Prevention of hypoglycaemia in a patient with pancreatic microadenomatosis by a long-acting somatostatin analogue SMS 201-995.
Acute suppression of insulin secretion from pancreatic insulinomas by long-acting somatostatin analogue SMS 201-995 has been documented. We report the chronic use of the drug in a patient with persistent hypoglycaemia due to benign pancreatic microadenomatosis with satisfactory control of plasma glucose level and reduction of insulin production. There was no tachyphylaxis or untoward side-effect noted during the 6-month treatment period.
D000236:Adenoma / Q000150:complications* / Q000378:metabolism / Q000601:surgery; D005260:Female; D006801:Humans; D007003:Hypoglycemia / Q000188:drug therapy* / Q000209:etiology; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D008875:Middle Aged; D015282:Octreotide; D010180:Pancreatectomy; D010190:Pancreatic Neoplasms / Q000150:complications* / Q000378:metabolism / Q000601:surgery; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use
D007328:Insulin; D013004:Somatostatin; D015282:Octreotide